VistaGen Therapeutics, Inc.
http://www.vistagen.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From VistaGen Therapeutics, Inc.
Asia Deal Watch: US Biotech LIB Partners In Greater China With Hasten On PCSK9 Therapy
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
Vistagen Getting 'Back On Offense’ After US FDA Okays Endpoint For Its Social Anxiety Drug
CEO Shawn Singh discusses path forward for fasedienol (PH94B) using the classic LSAS primary endpoint in next clinical trial. Pherine nasal spray candidate failed to meet the primary endpoint (the patient-reported SUDS) in its first pivotal Phase III study, whose design was constrained by the Covid pandemic.
Deal Watch: Merck KGaA Teams Up With Mersana On STING Agonist ADCs
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
VistaGen Staggered By Latest Clinical Setback, This Time In Social Anxiety
Failure of pherine nasal spray candidate in first of two Phase III trials for social anxiety disorder puts program in doubt, while the California biotech’s share price craters.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Drug Discovery Technologies
- Gene Therapy, Cell Therapy
-
Drug Discovery Technologies
- ADMET
- Other Names / Subsidiaries
-
- VistaStem Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice